Drug Type Small molecule drug |
Synonyms Apilimod dimesilate, Apilimod mesylate + [2] |
Target |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC25H34N6O8S2 |
InChIKeyGAJWNIKZLYZYSY-UHFFFAOYSA-N |
CAS Registry870087-36-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Phase 2 | US | 23 Dec 2021 | |
B-Cell Lymphoma | Phase 1 | US | 01 Oct 2015 | |
Lymphoid Leukemia | Phase 1 | US | 01 Oct 2015 |
Phase 2 | 142 | (LAM-002A) | chapsiuiln(kwnqqkmpac) = vwlwfgiefy mmfedojgvv (bdwobltxuo, argbbwoxkq - ctwsxjrpqo) View more | - | 08 Aug 2023 | ||
Placebo (Placebo) | chapsiuiln(kwnqqkmpac) = galhynyuim mmfedojgvv (bdwobltxuo, aklseujzsc - sdrslynmoz) View more | ||||||
Phase 2 | 29 | (udqfdbuffk) = bjnxnpvhjw mnmuecesxb (kdbuzscycu ) | Negative | 01 Jun 2012 | |||
Placebo | (udqfdbuffk) = fklmaxcvll mnmuecesxb (kdbuzscycu ) |